SUPN SUPERNUS PHARMACEUTICALS revenue, earnings and financials
For the quarter ended June 30, 2026, SUPERNUS PHARMACEUTICALS reported revenue of $219M (up 32.4% from a year earlier), net income of −$58.4M and diluted EPS of −$1.01; over the last four quarters revenue was $830M and net income −$110M; for the fiscal year ended December 2025 revenue was $719M, up 8.6% on the year before.
SUPN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $719M, gross profit n/a, operating income −$62.3M, net income −$38.6M (margin -5.4%), EPS −$0.68
- Fiscal year ended Dec 2024: revenue $662M, gross profit n/a, operating income $81.7M, net income $73.9M (margin 11.2%), EPS $1.32
- Fiscal year ended Dec 2023: revenue $608M, gross profit n/a, operating income −$5.27M, net income $1.30M (margin 0.2%), EPS $0.02
- Fiscal year ended Dec 2022: revenue $667M, gross profit n/a, operating income $46.1M, net income $60.7M (margin 9.1%), EPS $1.04
- Fiscal year ended Dec 2021: revenue $580M, gross profit n/a, operating income $86.0M, net income $53.4M (margin 9.2%), EPS $0.98
SUPN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $219M (up 32.4% year over year), net income −$58.4M, EPS −$1.01
- Quarter ended Mar 31, 2026: revenue $208M (up 38.6% year over year), net income −$2.29M, EPS −$0.04
- Quarter ended Dec 31, 2025 (from the annual report): revenue $212M (up 21.5% year over year), net income −$4.16M, EPS −$0.07
- Quarter ended Sep 30, 2025: revenue $192M (up 9.3% year over year), net income −$45.1M, EPS −$0.80
- Quarter ended Jun 30, 2025: revenue $165M (down 1.7% year over year), net income $22.5M, EPS $0.40
- Quarter ended Mar 31, 2025: revenue $150M (up 4.3% year over year), net income −$11.8M, EPS −$0.21
- Quarter ended Dec 31, 2024 (from the annual report): revenue $174M (up 6.0% year over year), net income $15.4M, EPS $0.27
- Quarter ended Sep 30, 2024: revenue $176M (up 14.2% year over year), net income $38.5M, EPS $0.69
- Quarter ended Jun 30, 2024: revenue $168M (up 24.2% year over year), net income $19.9M, EPS $0.36
- Quarter ended Mar 31, 2024: revenue $144M (down 6.6% year over year), net income $124K, EPS $0.00
- Quarter ended Dec 31, 2023 (from the annual report): revenue $164M (down 1.8% year over year), net income $1.16M, EPS $0.04
- Quarter ended Sep 30, 2023: revenue $154M (down 13.2% year over year), net income −$16.0M, EPS −$0.29
- Quarter ended Jun 30, 2023: revenue $136M (down 20.3% year over year), net income −$831K, EPS −$0.02
- Quarter ended Mar 31, 2023: revenue $154M (up 0.8% year over year), net income $16.9M, EPS $0.29
- Quarter ended Dec 31, 2022 (from the annual report): revenue $167M (up 5.2% year over year), net income $25.5M, EPS $0.44
- Quarter ended Sep 30, 2022: revenue $177M (up 19.5% year over year), net income $1.75M, EPS $0.03
- Quarter ended Jun 30, 2022: revenue $170M (up 20.3% year over year), net income $7.87M, EPS $0.14
- Quarter ended Mar 31, 2022: revenue $153M (up 16.5% year over year), net income $25.6M, EPS $0.43
- Quarter ended Dec 31, 2021 (from the annual report): revenue $159M, net income $2.42M, EPS $0.04
- Quarter ended Sep 30, 2021: revenue $148M, net income $21.6M, EPS $0.40
SUPN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $47.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $172M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow $111M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $117M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $127M, share buybacks n/a
SUPN balance sheet
- Jun 30, 2026: cash $180M, total assets $1.43B, total liabilities $397M, shareholders' equity $1.03B
- Mar 31, 2026: cash $185M, total assets $1.50B, total liabilities $424M, shareholders' equity $1.08B
- Dec 31, 2025: cash $128M, total assets $1.45B, total liabilities $391M, shareholders' equity $1.06B
- Sep 30, 2025: cash $151M, total assets $1.42B, total liabilities $370M, shareholders' equity $1.05B
- Jun 30, 2025: cash $145M, total assets $1.38B, total liabilities $319M, shareholders' equity $1.06B
- Mar 31, 2025: cash $116M, total assets $1.35B, total liabilities $317M, shareholders' equity $1.03B
- Dec 31, 2024: cash $69.3M, total assets $1.37B, total liabilities $332M, shareholders' equity $1.04B
- Sep 30, 2024: cash $31.7M, total assets $1.34B, total liabilities $336M, shareholders' equity $1.01B
What is SUPN's revenue?
SUPERNUS PHARMACEUTICALS reported $830M of revenue over its last four quarters, through June 30, 2026.
Is SUPN profitable?
No. SUPERNUS PHARMACEUTICALS lost $110M over the last four quarters.
What is SUPN's EPS?
Diluted earnings per share over the last four quarters were −$1.92; −$1.01 in the latest quarter.